



SDI Review Form 1.6

Journal Name:	International Journal of Medical and Pharmaceutical Case Reports
Manuscript Number:	Ms_IJMPCR_45145
Title of the Manuscript:	Primary breast lymphoma with delay response to treatment: a case report
Type of the Article	Case study

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	Is this case can be explained at the molecular level?? Are any genes involved in the development of this type of breast lymphoma??	Molecular survey is not performed in this study however According to second edition of breast pathology by David J DABS in 2017 phenotypic And cytogenetic features of this type of breast lymphoma is explain in table 35-2 , as following : 20- 30 % : BCL2 30% : BCL6 Re arrangement of MYC gene : less than 10 %
Minor REVISION comments	Punctuation should be considered. Many sentences began with small letter with uppercase letter in the middle of the sentence.	
Optional/General comments		

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	(If yes, Kindly please write down the ethical issues here in details)	